Acesso livre
Acesso livre

Clínica Médica

Relatório do CDC | Vacina da Moderna está associada a alta efetividade (93%) contra hospitalização por Covid-19 em comparação às vacinas da Pfizer (88%) e da J&J (71%).

20 Set, 2021 | 13:59h

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021 – CDC Morbidity and Mortality Weekly Report

Comentários:

Moderna’s vaccine is the most effective, but Pfizer and J&J also protect well, CDC-led study says – CNN

CDC: Moderna COVID vaccine most protective against hospital cases – CIDRAP

CDC data: Moderna vaccine has edge in preventing COVID-19 hospitalizations – UPI

 

Comentário no Twitter

 


Um painel da FDA afirma que somente americanos de alto risco e os maiores de 65 anos deveriam tomar as doses de reforço contra Covid.

20 Set, 2021 | 13:56h

An FDA Panel Says Only High-Risk Americans And Those 65+ Should Get COVID Boosters – NPR

Ver também:

FDA advisory panel recommends booster doses of Covid-19 vaccine only for older and high-risk Americans – STAT

5 reasons why FDA advisers did not recommend Covid-19 booster shots for everyone – CNN

Top doctors say not so fast to Biden’s boosters-for-all plan – Associated Press

Conteúdos relacionados:

An observational study in Israel suggests additional protection from a 3rd dose of the Pfizer vaccine in individuals 60 years of age or older.

Third shot: UK to offer COVID booster jabs to over 50s.

COVID-19 vaccine efficacy does not support boosters for general population, review concludes.

COVID vaccine effects wane over time but still prevent death and severe illness.

What’s the evidence for COVID-19 booster shots?

WHO appeals for countries to postpone COVID-19 vaccine boosters until 2022 to prioritize vaccinating the most at-risk people around the world who are yet to receive their first dose.

AstraZeneca bosses warn against rush for boosters – “giving the most vulnerable, who may not have built up a full immune response from the first two, a third, top-up dose is “sensible”. But any decision to give a third, booster jab “to large swathes of the population”, to extend their protection from the first two, must be based on clinical data”.


Todos precisam de dose de reforço? – “Por que algumas pessoas poderiam precisar de uma dose de reforço de vacina contra Covid-19 – e outras, não.”

20 Set, 2021 | 13:54h

Does everybody need a booster shot? – Vox


Imunidade conferida pela vacina contra COVID está caindo: o quanto isso importa? – “Enquanto os debates sobre as doses de reforço se acirram, o que se sabe sobre a duração da imunidade baseada em vacina ainda está em evolução.”

20 Set, 2021 | 13:51h

COVID vaccine immunity is waning — how much does that matter? – Nature


Doença hepática gordurosa não alcoólica: uma diretriz para o paciente.

20 Set, 2021 | 13:48h

Non-alcoholic fatty liver disease: A patient guideline – JHEP Reports

 

Comentário no Twitter

 


Amplo estudo de coorte sugere que a substituição de rotina de cateteres intravenosos periféricos (a cada 96 horas) pode reduzir o risco de infecções sanguíneas em comparação à substituição indicada clinicamente.

20 Set, 2021 | 13:47h

Comparison of Routine Replacement With Clinically Indicated Replacement of Peripheral Intravenous Catheters – JAMA Internal Medicine (gratuito por tempo limitado)

Revisão Cochrane relacionada, com diferentes achados: Systematic Review: Clinically‐indicated vs. Routine Replacement of Peripheral Venous Catheters

 

Comentário no Twitter

 


Efeitos adversos em um estudo comparando estatina, placebo e nenhum tratamento – Este estudo N-de-1, agora publicado na totalidade, sugere que o efeito de “nocebo” causa a maioria dos efeitos adversos musculares das estatinas.

20 Set, 2021 | 13:45h

Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment – Journal of the American College of Cardiology

Ver também: #AHA20 – In patients who had discontinued statins because of side effects, a N-of-1 trial of a statin, placebo, or no treatment found that side effects often attributed to statins were the same for those taking a placebo


Estudo randomizado | Rivaroxabam não tem impacto sobre a progressão da doença e a resolução dos sintomas em adultos de alto risco com COVID-19 leve.

17 Set, 2021 | 13:12h

Randomized study of rivaroxaban vs. placebo on disease progression and symptoms resolution in high-risk adults with mild COVID-19 – Clinical Infectious Diseases


Tratamento de sobreviventes de UTI de COVID-19 na atenção primária: uma revisão narrativa.

17 Set, 2021 | 13:08h

Management of COVID-19 ICU-survivors in primary care: – a narrative review – BMC Family Practice


COVID-19 na gastrenterologia: onde estamos agora? Evidências atuais sobre o impacto da COVID-19 na gastrenterologia.

17 Set, 2021 | 13:06h

COVID-19 in gastroenterology: Where are we now? Current evidence on the impact of COVID-19 in gastroenterology – UEG Journal


Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.